Outpatient adherence to risperidone long-acting injection following discharge from a state psychiatric hospital

American Journal of Pharmacy Benefits

Volumn 3, Issue 5, 2011, Pages 284-290

  Purvis, Tara L ^a,d   Nelson, Leigh Anne ^b   Elliott, Ellie S R ^a   Hieber, Robin N ^a   Liu, Yifei ^b   Pham, Richard H ^a,d   Munro, Stuart ^a,c   Sommi, Roger W ^b,c  

^a Western Missouri Mental Health Center   (United States)

^b Division of Pharmacy Practice and Administration   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d Veterans Affairs Sierra Nevada Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING DRUG; RISPERIDONE;

ACUTE PSYCHOSIS; ADULT; COMMUNITY MENTAL HEALTH CENTER; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; MENTAL HEALTH CARE; MENTAL HOSPITAL; OUTCOME ASSESSMENT; OUTPATIENT CARE; PARANOID SCHIZOPHRENIA; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREDICTION; RETROSPECTIVE STUDY; REVIEW; TREATMENT REFUSAL;

EID: 84859744026     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247.
2. Olfson M, Mechanic D, Boyer CA, et al. Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis. 1999;187(12):721-729.
3. Pyne JM, McSweeney J, Kane HS, et al. Agreement between patients with schizophrenia and providers on factors of antipsychotic medication adherence. Psychiatr Serv. 2006;57(8):1170-1178.
4. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23(4): 637-651.
5. Lacro JP, Dunn LB, Dolder CP, et al. Prevalence and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
6. Lacro J. Optimizing adherence to treatment in patients with schizophrenia. Behav Healthc. 2006;26(8):38-42.
7. Bice DP. The economic impact of schizophrenia. J Clin Psychiatry. 1999;60 (suppl 1):4-6; discussion 28-30.
8. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3): 419-429.
9. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs. 1994;47(5):741-773.
10. Adams CE, Fenton MKP, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179(4): 290-299.
11. Fuller M, Shermock K, Secic M, et al. Hospitalization and resource utilization in schizophrenia following initiation of risperidone long-acting injection in the veteran affairs healthcare system. Presented at the Collegium Internationale NeuroPsychopharmacologium 25th Biennial Congress; July 9-13, 2006; Chicago, IL.
12. Hugo EP, Givone DM. Hospitalization and medication compliance associated with the use of long-acting risperidone injection for the treatment of schizophrenia and schizoaffective disorder in a veteran population. Presented at the College of Psychiatric and Neurologic Pharmacists Annual Meeting; April 13-16, 2008; Scottsdale, AZ.
13. Kozma CM, Slaton T, Crivera C, et al. Resource use patterns over 24 months for patients with schizophrenia who initiated therapy with risperidone long-acting therapy. Presented at the College of Psychiatric and Neurologic Pharmacists Annual Meeting; April 13-16, 2008; Scottsdale, AZ.
14. Razali MS, Yahya H. Compliance with treatment in schizophrenia. Acta Psychiatry Scand. 1995;91(5):331-335.
15. Draine J, Solomon P. Explaining attitudes toward medication compliance among a seriously mentally ill population. J Nerv Ment Dis. 1994;182(1):50-54.
16. Taylor DM, Young C, Patel MX. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: favors predicting favourable outcome. Int J Neuropsychopharmacol. 2006;9(6):685-694.
17. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23(4): 637-651.
18. Weiss KA, Smith TE, Hull JW, et al. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull. 2002;28(2):341-349.
19. Barnes TR. Depot anitpsychotics drugs and prevention of psychotic relapse. Clin Neuropharmacol. 1991;14(suppl 2):S1-S6.
20. Barnes TRE, Curson DA. Long-acting depot antipsychotics: a risk-benefit assessment. Drug Saf. 1994;10(6):464-479.
21. Davis JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry. 1993;54(3 suppl):24-30.
22. Turner M, Eerdekens E, Jacko M, et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol. 2004;19(4):241-249.
23. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003:64(10): 1250-1257.
24. Leal A, Rosillon D, Mehnert A, et al. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf. 2004;13(11):811-816.
25. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand. 2006;114(1):14-20.
26. Taylor DM, Young C, Patel MX. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol. 2006;9(6):685-694.
27. Paton C, Okocha C. Risperidone long-acting injection: the first 50 patients. Psychiatrist. 2004;28(1):12-14.
28. Taylor DM, Young C, Mace S, et al. Early clinical experience with risperidone long acting injection prospective, 6-month follow up of 100 patients. J Clin Psychiatry. 2004;65(8):1076-1083.